Abstract: A pharmaceutical composition comprising a 4?-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.

Abstract: The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with ?-opioid receptor. The polyamide compound of the invention has excellent ?-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain.

Abstract: The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involving abnormal cell proliferation or a viral infectious disease.

Abstract: The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).

Abstract: Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Liquid-crystal compounds, liquid-crystal compositions, and liquid-crystal devices employing the same are provided. The liquid-crystal compound has a structure of Formula (I): wherein R1 is hydrogen, C1-10 alkyl, or C2-10 alkenyl; R2 is, C2-10 alkenyl, or C2-10 fluoroalkenyl, in which one or two nonadjacent —CH2— is replaced by —O—, or C2-10 ether; A1, A2, A3, and A4 are independently R3 is independently hydrogen, or halogen; Z1, Z2, and Z3 are independently single bond, —CH2—, —(CH2)2—, —(CH2)4—, —CH2O—, —OCH2—, —CF?CF—, —(CH2)2CF2O—, —(CH2)2OCF2—, —OCF2(CH2)2—, —CF2O(CH2)2—, —COO—, —OCO—, —CF2O—, —OCF2—, —C?C—, —CH?CH—, —CH?CH—(CH2)2—, or —(CH2)2—CH?CH—; and n and m are independently 1 or 0.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Liquid-crystal compounds, liquid-crystal compositions, and liquid-crystal devices employing the same are provided. The liquid-crystal compound has a structure of Formula (I): wherein R1 is hydrogen, C1-10 alkyl, or C2-10 alkenyl; R2 is, C2-10 alkenyl, or C2-10 fluoroalkenyl, in which one or two nonadjacent —CH2— is replaced by —O—, or C2-10 ether; A1, A2, A3, and A4 are independently R3 is independently hydrogen, or halogen; Z1, Z2, and Z3 are independently single bond, —CH2—, —(CH2)2—, —(CH2)4—, —CH2O—, —OCH2—, —CF?CF—, —(CH2)2CF2O—, —(CH2)2OCF2—, —OCF2(CH2)2—, —CF2O(CH2)2—, —COO—, —OCO—, —CF2O—, —OCF2—, —C?C—, —CH?CH—, —CH?CH—(CH2)2—, or —(CH2)2—CH?CH—; and n and m are independently 1 or 0.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.